A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Conditions: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Interventions: Drug: SHR-A1811; Drug: Trastuzumab Emtansine Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Conditions: Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Drug: Neratinib Maleate; Drug: Palbociclib Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Gut and Tumor Microbiome in Patients With Advanced ER-positive and HER2-negative Breast Cancer or Advanced Melanoma Undergoing PD-1 Checkpoint Inhibitor Therapy.
Conditions: Breast Cancer; Melanoma Interventions: Other: Observation Sponsors: BioCorteX Inc; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Conditions: Advanced Breast Cancer; Objective Response Rate; Trastuzumab Emtansine Interventions: Drug: Trastuzumab Emtansine (T-DM1) Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
HER-2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council
Conditions: Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer; Advanced Breast Cancer Interventions: Behavioral: Prolonged Overnight Fasting; Behavioral: Moderate-Intensity Exercise; Behavioral: General Health Education Sessions Sponsors: University of Miami; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Conditions: Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation Interventions: Drug: Pembrolizumab; Drug: Trastuzumab Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: SHR-A1811; Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Conditions: Breast Neoplasms Interventions: Procedure: Sentinel Lymph Node Biopsy (SLNB); Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-draining lymph node-derived lymphocyte (LNL); Biological: Interleukin-2; Drug: Nab-paclitaxel Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Conditions: Breast Neoplasms Interventions: Procedure: Surgery for harvesting tumor-draining lymph nodes; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-draining lymph node-derived lymphocyte (LNL); Biological: Interleukin-2; Biological: Camrelizumab; Drug: Chemotherapeutic drug, ADC or PARP inhibitor Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer Interventions: Drug: BGB-43395; Drug: Fulvestrant; Drug: Letrozole Sponsors: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: BL-M07D1 Sponsors: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Dato-DXd; Drug: Durvalumab; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Carboplatin; Drug: Capecitabine; Drug: Olaparib Sponsors: AstraZeneca; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Mobile Health for Adherence in Breast Cancer Patients
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Other: Electronic Health Record Review; Other: Health Promotion and Education; Procedure: Health Telemonitoring; Other: Interview; Behavioral: Patient Navigation; Other: Survey Administration; Other: Text Message-Based Navigation Intervention Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Conditions: GastroEsophageal Cancer; Gastric Cancer Interventions: Drug: Neratinib; Drug: Trastuzumab; Drug: Oxaliplatin; Drug: 5-Fluorouracil + leucovorin; Drug: Pembrolizumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Puma Biotechnology, Inc.; National Comprehensive Cancer Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
